TS
AVTX icon

Thomas Steyer’s Avalo Therapeutics AVTX Stock Holding History

Thomas Steyer’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2M Buy
2,498,000
+1,582,000
+173% +$25M 0.21% 41
2026
Q1 		$13.7M Buy
+916,000
New +$14.3M 0.07% 63

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Thomas Steyer's AVTX Position: Q2 2026 in Review

Thomas Steyer increased its Avalo Therapeutics (AVTX) stake by 173% in Q2 2026, buying an estimated $25M and bringing the position to 2,498,000 shares worth $46.2M. The position accounts for 0.21% of the portfolio, ranked #41.

Thomas Steyer first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Thomas Steyer held 2,498,000 shares of Avalo Therapeutics worth $46.2M as of Q2 2026.
  • Thomas Steyer bought 1,582,000 Avalo Therapeutics shares in Q2 2026, an estimated $25M.
  • Avalo Therapeutics made up 0.21% of Thomas Steyer's portfolio in Q2 2026, its #41 holding.
  • Thomas Steyer first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.